Home > Insider Trading > Filing (0001790340-24-000038)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1790340	Immuneering Corp	IMRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1941795	Mallory Morales	C/O Immuneering Corporation 245 Main Street, Second Floor Cambridge MA 02142	Chief Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2024-03-15	4,344	$1.62	6,778	No	4	A	Direct
Class A Common Stock	Acquisiton	2024-03-21	1,107	$2.72	7,885	No	4	P	Direct
Class A Common Stock	Acquisiton	2024-03-22	393	$2.55	8,278	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024.
In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.675 to $2.74. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.